Vimta Labs Surges 15.80% as Q1FY26 PAT Soars to ₹188.94 Cr; Heavy Volumes Trigger Momentum

Hyderabad, July 18, 2025: Vimta Labs Ltd (NSE: VIMTALABS, BSE: 524394) saw its shares surge by 15.80% to ₹539.55 in Friday afternoon trade, reflecting a gain of ₹73.60 over the previous close of ₹465.95. The stock touched an intraday high of ₹545.00 before settling near its peak, supported by robust trading volumes and positive financial results for Q1 FY26.

Stock Performance Snapshot (as of 18-Jul-2025, 3:00 PM IST)

The stock has also been among the Top 10 gainers on NSE today, highlighting strong investor confidence and buying interest.

Q1FY26 Results: Strong Revenue and Profit Growth

Vimta Labs reported a consolidated net profit of ₹188.94 crore for Q1 FY26, marking a significant year-on-year increase from ₹122.81 crore in Q1 FY25. Revenue from operations stood at ₹975.64 crore, up from ₹748.76 crore in the year-ago period. The company reported a total income of ₹993.13 crore. This strong performance indicates healthy growth in its core business.

Quarterly Financial Comparison

Strategic Developments

1. Bonus Issue Implemented

• On 14 June 2025, Vimta Labs issued 2,22,52,754 bonus shares in a 1:1 ratio, effectively doubling its paid-up equity capital to ₹44.51 crore. A bonus issue typically increases the number of shares in circulation, which can enhance liquidity and make the stock more attractive to a broader range of investors, potentially leading to increased trading volumes.

2. Discontinued Operations Adjusted

• The company had previously sold its diagnostics and pathology segment to Thyrocare Technologies under a slump sale in October 2024. This Q1 FY26 financial report includes no contribution from these discontinued operations, allowing for a clearer focus on the performance of its core segments.

3. Cost Auditor Transition

• The Board approved the appointment of Lavanya and Associates LLP as the new cost auditor for FY25 and FY26. This change was due to the firm’s conversion from a proprietorship to a Limited Liability Partnership (LLP).

Segment & Business Insights

Vimta Labs operates predominantly in a single segment: Contract Research and Testing Services. These services are crucial in the pharmaceutical, biotechnology, and medical device industries. Contract Research Organisations (CROs) like Vimta Labs provide specialised research support, including preclinical and clinical research, laboratory testing, data management, and regulatory compliance assistance. By outsourcing these functions, clients can save time and resources, streamline drug development, and ensure adherence to stringent regulatory standards.

The company’s revenue also includes earnings from its Public-Private Partnership (PPP) with FSSAI (Food Safety and Standards Authority of India) for running the National Food Testing Laboratory at JNPT, Mumbai. This partnership further diversifies its revenue streams and highlights its role in public health and safety. Additionally, an ESOP (Employee Stock Ownership Plan) allocation of 42,589 options was approved during the board meeting held on 17 July 2025, with related expenses of ₹15.19 million reflected in the employee cost, indicating an emphasis on employee incentives.

Market Outlook

The significant surge in Vimta Labs’ stock price is primarily driven by:

• Healthy financial performance with strong operational efficiency, as evidenced by the substantial increase in net profit and revenue.
• High delivery-based buying, which accounted for 15.28% of the traded volume, suggests that a considerable portion of shares traded are being held for investment rather than speculative purposes.
• Strong investor sentiment post-bonus issue, as the increase in share liquidity and perceived value has boosted confidence, coupled with robust margin visibility in its core testing and research services.

What’s Ahead?

With its core Contract Research and Testing Services showing robust growth, Vimta Labs is well-positioned to benefit from rising global demand for outsourced pharma and biotech R&D. The recent bonus issue and surge in volumes signal renewed investor interest, potentially supporting further re-rating if earnings momentum continues. Management’s strategic focus post-divestment of diagnostics may unlock greater margin stability. Key watchpoints ahead include sustained revenue growth, margin consistency, and client additions. If Q2 results reinforce this growth trajectory, the stock could see further upside, especially amid sectoral tailwinds and increased liquidity post-bonus.

About Vimta Labs Ltd

Vimta Labs Ltd, listed on NSE and BSE, is a Hyderabad-based contract research and testing company in the Healthcare Research Analytics & Technology domain. Incorporated in 1990, it serves a global clientele in pharma, biotech, food, and environmental sectors.

REF: https://nsearchives.nseindia.com/corporate/VIMTALABS_17072025144012_Reg_30.PDF

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations